Immunotherapy in Oncology

One of the biggest recent advances in cancer therapy has been the arrival of novel immunotherapies, such as anti-PD1 antibodies, which have demonstrated remarkable efficacy in multiple tumor types. In many instances supported by the ‘Breakthrough’ status granted by the FDA, many pharmaceutical companies are making huge efforts to bring these promising treatments to cancer patients in a timely fashion.

In this webinar, Rik de Greef discussed how modeling and simulation can support a focused and efficient development program for immunotherapies in cancer. Key challenges around dose selection, clinical pharmacology profiling and drug labeling were addressed through a variety of M&S techniques. Apart from discussing a conceptual framework for M&S in immuno-oncology, several practical applications were discussed, demonstrating the utility of M&S in this exciting area of drug development.